• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • News
    • News
    • DevTrivia

    On World Tuberculosis Day

    When was the BCG vaccine against tuberculosis first administered to humans? Know it?

    By Ivy Mungcal // 21 March 2012
    A vial and a syringe. Photo by: zethiel

    A world without tuberculosis — it’s an ambitious but sensible goal: TB is the second-largest infectious killer of adults worldwide, and people in developing countries are especially prone to the disease.

    One focus of international efforts to identify, treat and prevent TB is on the creation of new tuberculosis vaccines to prevent new infections.

    There is only one vaccine currently used to protect humans from tuberculosis: bacillus Calmette-Guérin, or BCG. It was named after French bacteriologist Albert Calmette and his colleague, the veterinarian Camille Guérin, who isolated the first strain of a weakened bacterium.

    BCG was first administered as a vaccine in 1921 to a group of infants. The World Health Organization estimates more than 1 billion people have since received the vaccine, whose various strains are now being produced in Tice, Montreal, Copenhagen and elsewhere.

    BCG protects infants and young children against extra pulmonary tuberculosis — so why the clamor for new vaccines?

    According to the Stop TB Partnership, BCGdoes not work for adolescents and adults, even after revaccination. The vaccine also does not protect against pulmonary tuberculosis, which is the most common form of the disease.

    The Stop TB Partnership hosts a special working group focused on the research and development of a new vaccine. This working group reports promising progress: 15 vaccine candidates entered clinical trials in 2011. An additional five were ready for clinical testing as of December 2011, while more than 20 are in the research and development stage.

    TB experts hope to identify three types of vaccines: an “improved” BCG, an early booster vaccine and a late booster for adults. To guide future vaccine research and development, the Stop TB Partnership has released a new blueprint outlining priorities for the next 10 years.

    To be sure, the development of new, safe and effective vaccines is only one step toward a world without tuberculosis. But it is an important campaign that deserves the global health community’s support.

    On World Tuberculosis Day this Saturday, March 24, you may lend your voice to the global fight against TB. It’s time, as U.N. Secretary-General Ban Ki-moon puts it, to end neglect of this disease.

    Read our previous DevTrivia.

    • Global Health
    • Funding
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Ivy Mungcal

      Ivy Mungcal

      As former senior staff writer, Ivy Mungcal contributed to several Devex publications. Her focus is on breaking news, and in particular on global aid reform and trends in the United States, Europe, the Caribbean, and the Americas. Before joining Devex in 2009, Ivy produced specialized content for U.S. and U.K.-based business websites.

    Search for articles

    Related Jobs

    • Individual Consultant: Health Education Capacity Building (Pesantren) Expert
      Jakarta, Indonesia | Indonesia | East Asia and Pacific
    • MEL Officer
      Haiti | Latin America and Caribbean
    • Individual Consultant: Health Financing - Assessment of Policy and International Coordination
      Central Asia | East Asia and Pacific | Oceania | South Asia
    • See more

    Most Read

    • 1
      Opinion: Mobile credit, savings, and insurance can drive financial health
    • 2
      FCDO's top development contractors in 2024/25
    • 3
      Strengthening health systems by measuring what really matters
    • 4
      Opinion: India’s bold leadership in turning the tide for TB
    • 5
      How AI-powered citizen science can be a catalyst for the SDGs

    Trending

    Financing for Development Conference

    The Trump Effect

    Newsletters

    Related Stories

    Global healthOpinion: TB is back as top infectious killer. AI can change that

    Opinion: TB is back as top infectious killer. AI can change that

    Global healthHow Trump’s aid freeze is threatening tuberculosis programs

    How Trump’s aid freeze is threatening tuberculosis programs

    Global HealthStop TB Partnership retains US funds but must revise scope, cut staff

    Stop TB Partnership retains US funds but must revise scope, cut staff

    Global healthUSAID funding cuts jeopardize breakthrough drugs and research

    USAID funding cuts jeopardize breakthrough drugs and research

    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement